Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,581 to 1,600 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Vitamins vs Placebo: Analysis of Primary Composite Outcome in Participants Randomized on or After the 13th Week of Pregnancy | 161 of 2,812 158 of 2,814 | 0.1 points -1.1 to 1.3 | 5,626 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| SMARTER CRC Intervention Year 1 vs Usual Care: Abnormal FIT Results | 19 of 2,613 7 of 3,001 | 0.5 points 0.1 to 0.9 | 5,614 | NCT04890054 Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC |
| Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) vs Arm 2: Main Cohort: Group 2: Placebo: Main Cohorts: Number of Participants With Any RT-PCR-confirmed RSV Disease | 13 of 2,791 43 of 2,801 | -1.1 points -1.6 to -0.6 | 5,592 | NCT03982199 A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older |
| 150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy: deaths from any cause | 38 of 2,791 36 of 2,800 | 0.1 points -0.5 to 0.7 | 5,591 | NCT03155997 Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer |
| 150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy: serious adverse events | 344 of 2,791 202 of 2,800 | 5.1 points 3.6 to 6.7 | 5,591 | NCT03155997 Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer |
| Conventional Axillary Dissection vs Sentinel Node Resection Followed by Node Examination: deaths from any cause | 0 of 2,788 1 of 2,800 | -0.0 points -0.2 to 0.1 | 5,588 | NCT00003830 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer |
| Conventional Axillary Dissection vs Sentinel Node Resection Followed by Node Examination: serious adverse events | 9 of 2,788 8 of 2,800 | 0.0 points -0.3 to 0.4 | 5,588 | NCT00003830 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer |
| Individualized Opioid Prescription (IOPP) -Neonates/Infants vs Fixed Opioid Prescription - Neonates/Infants: Infant Hospital Readmissions | 59 of 2,754 63 of 2,793 | -0.1 points -0.9 to 0.7 | 5,547 | NCT04296396 Opioid Prescription After Cesarean Trial |
| Lipid Trial: Fenofibrate vs Lipid Trial: Placebo: First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial. | 641 of 2,765 667 of 2,753 | -1.0 points -3.3 to 1.2 | 5,518 | NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) |
| Lipid Trial: Fenofibrate vs Lipid Trial: Placebo: First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial. | 291 of 2,765 310 of 2,753 | -0.7 points -2.4 to 0.9 | 5,518 | NCT00000620 Action to Control Cardiovascular Risk in Diabetes (ACCORD) |
| Abiraterone vs Enzalutamide: deaths from any cause | 2,523 of 2,911 2,176 of 2,595 | 2.8 points 0.9 to 4.7 | 5,506 | NCT05520138 Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) |
| Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With First Colposcopy | 392 of 2,741 422 of 2,738 | -1.1 points -3.0 to 0.8 | 5,479 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy | 76 of 2,740 84 of 2,737 | -0.3 points -1.2 to 0.6 | 5,477 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status | 152 of 2,740 178 of 2,737 | -1.0 points -2.2 to 0.3 | 5,477 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With First Colposcopy | 506 of 2,734 560 of 2,736 | -2.0 points -4.1 to 0.1 | 5,470 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status | 179 of 2,733 229 of 2,735 | -1.8 points -3.2 to -0.4 | 5,468 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| Cervarix Group vs Aluminium Hydroxide: Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy | 88 of 2,733 110 of 2,735 | -0.8 points -1.8 to 0.2 | 5,468 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| Odanacatib 50 mg OW vs Placebo (Originally Assigned to Placebo): Second Extension: Number of Participants Who Experienced an Adverse Event | 2,173 of 3,144 1,587 of 2,309 | 0.4 points -2.1 to 2.9 | 5,453 | NCT00529373 A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) |
| Odanacatib 50 mg OW vs Placebo (Originally Assigned to Placebo): Second Extension: Number of Participants Discontinuing Study Treatment Due to an Adverse Event | 55 of 3,144 36 of 2,309 | 0.2 points -0.5 to 0.9 | 5,453 | NCT00529373 A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) |
| Intervention - Fall Prevention Standard of Care vs Control: deaths from any cause | 235 of 2,802 220 of 2,649 | 0.1 points -1.4 to 1.6 | 5,451 | NCT02475850 Strategies to Reduce Injuries and Develop Confidence in Elders |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=80
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00135707-db72a3e3",
"title": "Vitamins vs Placebo: Analysis of Primary Composite Outcome in Participants Randomized on or After the 13th Week of Pregnancy",
"summary": "161 of 2812 against 158 of 2814; risk difference 0.1 points, 95% interval -1.1 to 1.3; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
"record": "/library/comparisons/NCT00135707-db72a3e3",
"nct_id": "NCT00135707",
"kind": "outcome",
"participants": 5626,
"risk_difference": {
"value": 0.0011067907768614813,
"lower": -0.011028500087935133,
"upper": 0.013248635880095205
},
"group_1": "161 of 2,812",
"group_2": "158 of 2,814",
"difference": "0.1 points",
"interval": "-1.1 to 1.3",
"trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
},
{
"id": "NCT04890054-1cb05da2",
"title": "SMARTER CRC Intervention Year 1 vs Usual Care: Abnormal FIT Results",
"summary": "19 of 2613 against 7 of 3001; risk difference 0.5 points, 95% interval 0.1 to 0.9; NCT04890054, Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC",
"record": "/library/comparisons/NCT04890054-1cb05da2",
"nct_id": "NCT04890054",
"kind": "outcome",
"participants": 5614,
"risk_difference": {
"value": 0.0049387798148161615,
"lower": 0.001341158813484039,
"upper": 0.009171052652613065
},
"group_1": "19 of 2,613",
"group_2": "7 of 3,001",
"difference": "0.5 points",
"interval": "0.1 to 0.9",
"trial_title": "Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=81",
"request_id": "Ep2Vzv4GABpZQ4HN"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant